Morepen Proprietary Drug Research Pvt Ltd

Morepen Proprietary Drug Research Pvt. Ltd. (MPDRPL) is a cutting-edge pharmaceutical R&D company, transforming the ways drugs are discovered and developed. Focused on New Chemical Entities (NCEs), Novel Drug Delivery Systems (NDDS), and next-generation drug delivery models, MPDRPL harnesses advanced digital technologies including AI/ML to accelerate innovation, streamline drug development, and deliver affordable therapies faster. Innovation at the Core: • AI/ML-Driven Drug Discovery & Formulation: By adopting a digital-first approach, MPDRPL minimizes reliance on traditional lab methods, driving faster and cost-efficient drug development. • Speed to Market: Leveraging AI/ML, MPDRPL significantly reduces cycle times to discover an NCE, enabling quicker transitions from discovery to clinical trials and accelerating access to essential therapies. • Ethical Research: We prioritize reducing animal testing by using alternative models, aligning with our commitment to both ethical innovation and sustainability. Leadership with Proven Expertise: MPDRPL is led by a team of industry experts who have successfully filed and received approvals of numerous New Drug Applications (NDAs) including both 505(b)(1) and 505(b)(2) by US FDA and also launched many products to global markets. Our leadership team's deep expertise in API development, drug discovery, regulatory strategy, and lifecycle management makes MPDRPL a forward-thinking and trusted partner in the pharmaceutical industry. Our Focus Areas: • New Drug Discovery: Through integrated drug discovery efforts, MPDRPL is focused on developing NCEs and advancing molecules via licensing and co-development partnerships. • Differentiated Product Development: MPDRPL works on the development of innovative formulations for existing drugs, enhancing their efficacy, safety, and patient compliance to meet unmet medical needs.